

ASX Announcement
19 February 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Reveals InForm™ Imaging Device for Pathology

This ground-breaking first-of-its-kind pathology imaging device is set to improve efficiency and accuracy of analysis and diagnosis across all pathology workflows.

Highlights

- Optiscan reveals InForm™, its next generation microscopic medical imaging device specifically designed for pathology workflows.
- InForm™ expands Optiscan's product portfolio into the pathology market, marking a pivotal milestone in advancing the Company's strategic objectives.
- InForm™ can be used in a variety of pathology settings, most notably in laboratory medicine, pathology practice, point-of-care and digital pathology.
- InForm™ is designed to enhance the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities.

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company') is pleased to announce the reveal of InForm™, a groundbreaking microscopic medical imaging device specifically designed to transform pathology by delivering real-time digital insights across the full pathology workflow at point of contact with a tissue sample. The device has been designed and manufactured in Melbourne by Optiscan in partnership with industrial design firm Design + Industry.

Optiscan's InForm™ device a new frontier in clinical pathology

InForm™ extends Optiscan's product range and marks a pivotal advancement in the Company's strategic portfolio expansion. Utilizing Optiscan's proprietary technology, this device is crafted specifically for pathologists and pathology technicians to obtain immediate insights to improve diagnostics across laboratory medicine, pathology practice and point-of-care practices to enhance real-time decision-making and redefine diagnostic workflows.

This represents a new frontier in clinical pathology by propelling real-time digital insights to the forefront of diagnostics. Through InForm™, Optiscan is reshaping traditional practices, enabling faster, more accurate decision-making, and supporting a seamless transition to digital pathology. This foray into a new clinical sphere represents a significant step forward for the Company, providing pathologists and clinicians with innovative tools to enhance patient care, reduce diagnostic delays, and address the growing demand for precision medicine. The device has the power to transform not just how we diagnose diseases, but also how we care for patients—bringing precision medicine and personalised care closer than ever before.



Optiscan CEO and Managing Director, Dr Camile Farah, said:

“The reveal of our revolutionary InForm™ device, the latest addition to our ever-expanding suite of hardware products, represents a significant advancement in the evolution of digital pathology. InForm™ has the ability to enhance the entire pathology workflow from bedside to laboratory and beyond, by improving the speed, accuracy and flexibility of testing, analysis and diagnosis. It is designed to be the point-of-contact digital workhorse of the pathology laboratory, providing immediate insights to the pathologist, facilitating triaging of samples, immediate decision making and diagnostic potential, and a revolutionary change to the analogue workflows encountered in most pathology labs. Through innovations such as InForm™, Optiscan’s stated intention to deliver faster, more accurate, and more accessible diagnostics is becoming a reality.”

Dr Farah added: “While tissue pathology has always been a critical component of modern medical practice, it has, until now, lagged behind radiology and diagnostic imaging in not adopting end-to-end digital workflows from

patient to report. Adapting our patented technology for the pathology market signifies a revolutionary leap towards this goal. With InForm™, Optiscan is proud to be taking a leading position in this space, as we aim to transform pathology practice with real-time point-of-care digital imaging. Our “digital first” approach targets delivery of faster workflows with unparalleled diagnostic yield and high accuracy, when compared to physical glass slide digitisation, which adds more steps and cost to an already time-consuming and complicated process. We now look forward to updating the market on further InForm™ device-specific developments over coming months, including its planned integration with Optiscan’s cloud-based telepathology streaming platform.”

InForm™ device to target a large and growing global market

Laboratory medicine spans a wide range of tests on blood, tissue, and other samples, providing essential insights into diseases such as diabetes and cancer. The global anatomic pathology market is projected to reach US\$53.27 billion by 2031¹, reflecting its critical role in modern medicine where pathology supports up to 70% of all clinical decisions².

Traditionally, tissue pathology has been a slow and fragmented process, dependent on analogue workflows, multiple time-intensive procedures, resource-intense slide preparation, and delayed interpretation and result generation. Optiscan's cutting-edge imaging technology transforms this approach by delivering point-of-care digital pathology insights, streamlining workflows, and enhancing both diagnostic efficiency and precision.

The InForm™ device has been designed specifically for ease of use across the full spectrum of anatomical pathology applications. These extend across fresh single sample diagnoses in the operating room (OR), specimen margin assessment adjacent to the OR, frozen section biopsy replacement for more immediate assessments during surgery, to routine laboratory assessments on fresh or fixed tissue generating digital microscopic images. The latter images are comparable to those obtained with benchtop white light microscope using traditional histopathology methodologies, but without any time-consuming or complicated tissue processing.

The InForm™ device has a spatial resolution of 0.55, offering up to 1000x real magnification at point-of-care, compared to the traditional 40-100x magnification on conventional light microscopes. Importantly, the device produces digital images instantly, and does not use any consumables beyond the topical dye preferred by the pathologist assessing the tissue.

The InForm™ is DICOM-compliant and PACS-enabled, allowing the device to be connected to hospital or laboratory archiving systems in a fashion similar to that of radiology platforms such as CT or MRI. This is a unique and intentional feature for a pathology device, and is a key enabler for seamless adoption and integration of digital pathology into the wider healthcare space, one that has lagged behind diagnostic radiology by decades. Additionally, the device is designed to integrate with Optiscan's cloud-based telepathology streaming platform, which allows remote consultation in real time anywhere in the world, and which is expected to be revealed in mid-2025.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

Optiscan Imaging Ltd (ASX:OIL)

16 Miles St, Mulgrave VIC 3170, Australia • www.optiscan.com • ABN: 81 077 771 987

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.

1. <https://www.globenewswire.com/news-release/2024/10/18/2965498/0/en/Anatomic-Pathology-Market-Size-Worth-53-27-Billion-Globally-by-2031-Exclusive-Report-by-The-Insight-Partners.html>
2. <https://pmc.ncbi.nlm.nih.gov/articles/PMC3799218/>